1,3-dihydro-1-methyl-4,5-diphenyl-2H-imidazol-2-one | 3653-23-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1,3-dihydro-1-methyl-4,5-diphenyl-2H-imidazol-2-one
• 英文别名: 1-methyl-4,5-diphenyl-1,3-dihydro-2H-imidazol-2-one；1-methyl-4,5-diphenyl-1H-imidazol-2(3H)-one；1-methyl-4,5-diphenylimidazol-2(3H)-one；1-methyl-4,5-diphenyl-2-imidazolone；1-methyl-4,5-diphenyl-1,3-dihydro-imidazol-2-one；1-Methyl-4,5-diphenyl-1,3-dihydro-imidazol-2-on；4.5-Diphenyl-1-methyl-4-imidazolin-2-one；3-methyl-4,5-diphenyl-1H-imidazol-2-one
• CAS: 3653-23-4
• 化学式: C₁₆H₁₄N₂O
• 分子量: 250.3
• InChiKey: IFMHYYJGRMAPFX-UHFFFAOYSA-N

物化性质

• 熔点：
  284-287 °C (decomp)(Solv: methanol (67-56-1))
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  1,3-dihydro-1-methyl-4,5-diphenyl-2H-imidazol-2-one 在 正丁基锂 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 17.5h， 生成 benzyl 4,5-diphenyl-1-methylimidazole-2-carboxylate
  参考文献：
  名称：

  Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

  摘要：

  Structure-activity relationship studies directed toward the optimization of 4,5-diarylimidazole-2-carboxamide analogs as human CBI receptor inverse agonists resulted in the discovery of the two amide derivatives 24a and b (hCB1 IC50 = 6.1 and 4.0 nM) which also demonstrated efficacy in overnight feeding studies in the rat for reduction in both food intake and overall body weight. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.078
• 作为产物：
  描述：

  1-methyl-4,5-diphenyl-1H-imidazole 3-oxide 在 1,1-双(三氟甲基)-2,2-二氰基乙烯 、 水 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 以73%的产率得到1,3-dihydro-1-methyl-4,5-diphenyl-2H-imidazol-2-one
  参考文献：
  名称：

  2-未取代的1 H-咪唑3-氧化物与2,2-双（三氟甲基）乙烯-1,1-二碳腈的反应：逐步1,3,2-偶极环加成

  摘要：

  1,4,5-三取代的1 H-咪唑-3-氧化物1与2,2-双（三氟甲基）乙烯-1,1-二碳腈（7，BTF）的反应生成相应的1,3-二氢-2 H-咪唑-2-酮10和2-（1,3-二氢-2 H-咪唑-2-亚烷基）丙二腈11，这取决于所使用的溶剂。在一个实施例中，分离出1 H-咪唑3-氧化物和六氟丙酮水合物的1：1络合物12作为第二产物。产物的形成通过逐步的1，3-偶极环加成和随后的断裂来解释。11d和12的结构 通过X射线晶体学确定。

  DOI：

  10.1002/hlca.200690129

文献信息

• N-Substituted .omega.-(2-oxo-4-imidazolin-1-yl) alcanoic acids and salts
  申请人：A. Nattermann & Cie GmbH

  公开号：US04349684A1

  公开（公告）日：1982-09-14

  The present invention refers to N-substituted .omega.-(2-oxo-4-imidazolin-1-yl) alcanoic acids as well as salts and esters thereof having the general formula I ##STR1## The compounds are useful, for example, as antiallergics, antiasthmatics, etc.

  本发明涉及N-取代的ω-(2-氧代-4-咪唑啉-1-基)脂肪酸及其盐和酯，其具有一般式I。这些化合物可用作抗过敏剂、抗哮喘剂等。
• Palladium-Catalyzed Cross-Coupling Reaction of Haloazoles with Phenylsulfonylacetonitrile
  作者：Takao Sakamoto、Yoshinori Kondo、Takashi Suginome、Setsuya Ohba、Hiroshi Yamanaka

  DOI：10.1055/s-1992-26163

  日期：——

  Condensation of halo-substituted 1,3-azoles (1,3-oxazoles, 1,3-thiazoles and imidazoles) with phenylsulfonylacetonitrile under basic conditions was promoted by catalytic action of tetrakis(triphenylphosphine)palladium(0) to give α-phenylsulfonyl-1,3-azoleacetonitriles. The adaptability of halogen atoms for the cross-coupling reaction was investigated. The reaction of 4-halo-1,2-azoles was also examined.

  在四(三苯基膦)钯(0)的催化作用下，经由卤代1,3-唑（1,3-噁唑、1,3-噻唑及咪唑）与苯磺酰丙腈在碱性条件下的缩合反应，合成了α-苯磺酰基-1,3-唑乙腈类化合物。探讨了卤素原子在交叉耦合反应中的适应性，并对4-卤代1,2-唑的反应进行了研究。
• Substituted imidazoles as cannabinoid receptor modulators
  申请人：——

  公开号：US20030114495A1

  公开（公告）日：2003-06-19

  The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1) receptor. As such, compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Novel compounds of structural formula (I) are also claimed.

  本发明涉及将这些新型化合物用于选择性拮抗Cannabinoid-1（CB1）受体。因此，本发明的化合物可用作治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎症性疾病（包括多发性硬化症和吉兰-巴雷综合征）、病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病和精神分裂症的精神药物。这些化合物还可用于治疗物质滥用障碍，特别是阿片类药物、酒精和尼古丁。这些化合物还可用于治疗与过度食物摄入及相关并发症相关的肥胖或进食障碍。同时还声明了结构式（I）的新型化合物。
• Unexpected reductive transformation of 1-substituted 5-hydroxy-4,5-diphenyl-1 H -imidazol-2(5 H )-ones and their cyclic analogs by the reaction with thiourea and hydrochloric acid
  作者：Vladimir V. Baranov、Maria M. Antonova、Valentina A. Karnoukhova、Angelina N. Kravchenko

  DOI：10.1016/j.tetlet.2017.04.061

  日期：2017.6

  1-substituted 5-hydroxy-4,5-diphenyl-1H-imidazol-2(5H)-ones (imidazolones) and their cyclic analogs to give 1-substituted 4,5-diphenyl-1H-imidazol-2(5H)-ones (imidazolinones) upon reaction with thiourea and hydrochloric acid was discovered.

  1-取代的5-羟基-4,5-二苯基-1 H-咪唑-2（5 H）-ones（咪唑啉酮）及其环状类似物的意外还原反应生成1-取代的4,5-二苯基-1 H与硫脲和盐酸反应后，发现了-咪唑-2（5 H）-酮（咪唑啉酮）。
• N-substituted omega-(2-oxo-4-imidazolin-1-yl) alcanoic acids, salts and esters thereof, process for producing the same and these active agents containing pharmaceutical compounds
  申请人：A. Nattermann & Cie. GmbH

  公开号：EP0051829A1

  公开（公告）日：1982-05-19

  the present invention refers to new N-substituted ω-(2-oxo-4-imidazolin-1-yl) alcanoic acids as well as salts and esters thereof having the general formula I process for producing the same and these active agents containing pharmaceutical compounds.

  本发明是指新的 N-取代ω-(2-氧代-4-咪唑啉-1-基)辛酸及其具有通式 I 的盐和酯，以及这些含有药物活性剂的化合物的生产工艺。